An attractive investment opportunity
We are an innovative vaccine company with an attractive product portfolio operating in an attractive market. Value-driving milestones over the next 24 month will add significant value to Themis, placing the company in a strong position to both seek partnerships and explore acquisition possibilities offering investors attractive exit scenarios over the next five years.
Anticipated milestones in the next 24 months:
Lead Product Dengue virus vaccine:
- Preclinical proof-of-concept for our Dengue vaccine
- GMP Manufacturing Dengue
- Start Phase I Dengue
Other candidates
- Preclinical proof-of-concept Chikungunya Vaccine
- Start Phase I Chikungunya Vaccine
These milestones will add significant value to Themis, placing the company in a strong position to both seek partnerships and explore acquisition possibilities offering investors attractive exit scenarios over the next five years.
If you are interested in this investment opportunity, please find more detailed information in our download area and do not hesitate to contact us. We will be happy to provide you with our business plan.